BENLYSTA for Intravenous Injection / Subcutaneous Injection Special Drug Use Investigation
Phase of Trial: Phase IV
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Belimumab (Primary) ; Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 09 Feb 2018 Status changed from not yet recruiting to recruiting.
- 20 Dec 2017 Planned initiation date changed from 13 Dec 2017 to 31 Jan 2018.
- 20 Dec 2017 New trial record